Results 161 to 170 of about 5,019 (231)

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager. [PDF]

J Mol Med (Berl)
Ebrahimi S, Lohnes BJ, Khan SA, Peipp M, Bockamp E, Klein C, Abken H, Wölfel C, Theobald M, Hartwig UF.   +9 more
europepmc   +1 more source

Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro. [PDF]

PLoS One
Kitidee K, Amonyingcharoen S, Preedagasamzin S, Atjanasuppat K, Sawaisorn P, Srimorkun P, Petvises S, Chaicumpa W, Borwornpinyo S, Anurathapan U, Hongeng S.   +10 more
europepmc   +1 more source

A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies. [PDF]

Mol Cancer Ther
Abayasiriwardana K, Wu L, Laklai H, Nocula-Lugowska M, Tchistiakova L, Narula J, Jackson-Fisher A, Golas J, Lam MH, Grinstein V, Kang JW, Kearney JC, Hosselet C, Upeslacis E, Lemon L, Zhang Y, Ji C, Buetow BS, Finkelstein MB, Marshall N, Bisulco S, Rosfjord E, Mathur D, Athanacio J, Thomas A, Trageser A, Fernandez D, Jiang ZK, Ram S, Cabral E, Manzuk L, Maresca K, Giddabasappa A, Lees C, Hooper AT, Sapra P, Chintharlapalli S.   +36 more
europepmc   +1 more source

A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer. [PDF]

Breast Cancer Res
Wang F, Li W, Han G, Xie J, Bai X.
europepmc   +1 more source

Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V. [PDF]

Biomol Biomed
Lu C, Zou L, Wang Q, Sun M, Shi T, Xu S, Meng F, Du J.   +7 more
europepmc   +1 more source

BCL‐2 and MCL1 co‐inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A‐rearranged acute lymphoblastic leukaemia

British Journal of Haematology, Volume 209, Issue 2, Page 786-792, August 2026.
Mawar Karsa, Ayu Karsa, Dayna Spurling, Lin Xiao, Emma Ronca, Angelika Bongers, Weiman Gao, Andrew J. Gifford, Ali El‐Ayoubi, Laurence C. Cheung, Rishi S. Kotecha, Richard B. Lock, Charis E. Teh, Guillaume Lessene, Murray D. Norris, Andrew Wei, Michelle Haber, Michelle J. Henderson, Donia M. Moujalled, Klaartje Somers   +19 more
wiley   +1 more source

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. [PDF]

J Clin Oncol
Stein MN, Vinceneux A, Robbrecht D, Doger B, Autio KA, Schweizer MT, Calvo E, Medina L, Van Dongen M, Deville JL, Bernard-Tessier A, Ghosh D, Shotts K, Shen F, Jaiprasart P, Chaudhary R, Wu S, Cartee L, Schnepp R, Gaut D, Lauring J, Wang SC, Villalobos VM, Baldini C.   +23 more
europepmc   +1 more source

A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia. [PDF]

Cell Mol Life Sci
Zeng X, Zhang H, Guo J, Yang D, Zhu Y, Liu N, Tang J, Liu T, Zhao X.   +8 more
europepmc   +1 more source

Author Correction: Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells. [PDF]

Sci Rep
Wathikthinnakon M, Luangwattananun P, Sawasdee N, Chiawpanit C, Lee VS, Nimmanpipug P, Tragoolpua Y, Rotarayanont S, Sangsuwannukul T, Phanthaphol N, Wutti-In Y, Somboonpatarakun C, Chieochansin T, Junking M, Sujjitjoon J, Yenchitsomanus PT, Panya A.   +16 more
europepmc   +1 more source

Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager. [PDF]

iScience
King LA, Veth M, Iglesias-Guimarais V, Blijdorp I, Kloosterman J, Vis AN, Roovers RC, Hulsik DL, Riedl T, Adang AEP, Parren PWHI, van Helden PM, de Gruijl TD, van der Vliet HJ.   +13 more
europepmc   +1 more source